Clinical Trial Update: Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID) [Phase 3]

View source ↗

Summary

Phase 3 trial LIBERTY-CSU CUPID evaluated dupilumab for chronic spontaneous urticaria in patients who remained symptomatic despite H1 antihistamines and were na…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• DUPIXENT (DUPILUMAB)

Snippet

Sponsor: Sanofi | Conditions: Chronic Spontaneous Urticaria | Phase 3 | Status: COMPLETED | Results posted: 2025-08-20